125 related articles for article (PubMed ID: 37832476)
1. Development and validation of a sensitive LC-MS/MS method for the assay of four PARP inhibitors in human plasma and its application in ovarian cancer patients.
Wei Y; Liang H; Liu S; Guan S; Ma K; Guan Y; Chen Y; Huang M; Wang X; Lan C
J Pharm Biomed Anal; 2024 Jan; 237():115758. PubMed ID: 37832476
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of a sensitive LC-MS/MS method for determination of gefitinib and its major metabolites in human plasma and its application in non-small cell lung cancer patients.
Guan S; Chen X; Wang F; Xin S; Feng W; Zhu X; Liu S; Zhuang W; Zhou S; Huang M; Wang X; Zhang L
J Pharm Biomed Anal; 2019 Aug; 172():364-371. PubMed ID: 31096095
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of an integrated LC-MS/MS assay for therapeutic drug monitoring of five PARP-inhibitors.
Bruin MAC; de Vries N; Lucas L; Rosing H; Huitema ADR; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Feb; 1138():121925. PubMed ID: 31915109
[TBL] [Abstract][Full Text] [Related]
4. A validated LC-MS/MS method for determination of neuro-pharmacokinetic behavior of niraparib in brain tumor patients.
Knight W; Margaryan T; Sanai N; Tovmasyan A
J Pharm Biomed Anal; 2024 Aug; 245():116150. PubMed ID: 38657366
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of a liquid chromatography coupled with tandem mass spectrometry method for determining total and unbound pamiparib in human plasma and brain tumors.
Jiang J; Bao X; Yue Y; Schiff D; Bindra R; Li J
Biomed Chromatogr; 2022 Dec; 36(12):e5478. PubMed ID: 35938683
[TBL] [Abstract][Full Text] [Related]
6. Method development and validation for simultaneous determination of six tyrosine kinase inhibitors and two active metabolites in human plasma/serum using UPLC-MS/MS for therapeutic drug monitoring.
Zhang M; Liu X; Chen Z; Jiang S; Wang L; Tao M; Miao L
J Pharm Biomed Anal; 2022 Mar; 211():114562. PubMed ID: 35124453
[TBL] [Abstract][Full Text] [Related]
7. Development and Validation of High-Throughput Bioanalytical Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Method for the Quantification of Newly Synthesized Antitumor Carbonic Anhydrase Inhibitors in Human Plasma.
Abdel-Megied AM; Eldehna WM; Abdelrahman MA; Elbarbry FA
Molecules; 2020 Dec; 25(23):. PubMed ID: 33291270
[TBL] [Abstract][Full Text] [Related]
8. Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC-MS/MS.
Krens SD; van der Meulen E; Jansman FGA; Burger DM; van Erp NP
Biomed Chromatogr; 2020 Mar; 34(3):e4758. PubMed ID: 31758580
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay quantifying olaparib in human plasma.
Nijenhuis CM; Lucas L; Rosing H; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Dec; 940():121-5. PubMed ID: 24145016
[TBL] [Abstract][Full Text] [Related]
10. LC-MS/MS Method for the Quantification of PARP Inhibitors Olaparib, Rucaparib and Niraparib in Human Plasma and Dried Blood Spot: Development, Validation and Clinical Validation for Therapeutic Drug Monitoring.
Canil G; Orleni M; Posocco B; Gagno S; Bignucolo A; Montico M; Roncato R; Corsetti S; Bartoletti M; Toffoli G
Pharmaceutics; 2023 May; 15(5):. PubMed ID: 37242766
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous and enantiospecific quantification of primaquine and carboxyprimaquine in human plasma using liquid chromatography-tandem mass spectrometry.
Hanpithakpong W; Day NPJ; White NJ; Tarning J
Malar J; 2022 Jun; 21(1):169. PubMed ID: 35659684
[TBL] [Abstract][Full Text] [Related]
12. Liquid chromatography-tandem mass spectrometry assay for the quantification of niraparib and its metabolite M1 in human plasma and urine.
van Andel L; Zhang Z; Lu S; Kansra V; Agarwal S; Hughes L; Tibben MM; Gebretensae A; Rosing H; Schellens JHM; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Jan; 1040():14-21. PubMed ID: 27898364
[TBL] [Abstract][Full Text] [Related]
13. Human mass balance study and metabolite profiling of
van Andel L; Zhang Z; Lu S; Kansra V; Agarwal S; Hughes L; Tibben MM; Gebretensae A; Lucas L; Hillebrand MJX; Rosing H; Schellens JHM; Beijnen JH
Invest New Drugs; 2017 Dec; 35(6):751-765. PubMed ID: 28303528
[TBL] [Abstract][Full Text] [Related]
14. Development of a simple high-performance liquid chromatography-ultraviolet detection method for olaparib in patients with ovarian cancer.
Yasu T; Nishijima R; Ikuta R; Shirota M; Iwase H
Drug Discov Ther; 2024 Jan; 17(6):428-433. PubMed ID: 38044120
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous quantitation of 17alpha-hydroxyprogesterone caproate, 17alpha-hydroxyprogesterone and progesterone in human plasma using high-performance liquid chromatography-mass spectrometry (HPLC-MS/MS).
Zhang S; Mada SR; Sharma S; Torch M; Mattison D; Caritis S; Venkataramanan R
J Pharm Biomed Anal; 2008 Dec; 48(4):1174-80. PubMed ID: 18947956
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous determination of 11 alkaloids in rat plasma by LC-ESI-MS/MS and a pharmacokinetic study after oral administration of total alkaloids extracted from Naucleaofficinalis.
Wang G; Wang H; Lin Z; Hou L; Wang JY; Sun L
J Ethnopharmacol; 2022 Jan; 282():114560. PubMed ID: 34454053
[TBL] [Abstract][Full Text] [Related]
17. A semi-automated LC-MS/MS method for the determination of LCI699, a steroid 11β-hydroxylase inhibitor, in human plasma.
Li W; Luo S; Rebello S; Flarakos J; Tse FL
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jun; 960():182-93. PubMed ID: 24814004
[TBL] [Abstract][Full Text] [Related]
18. Determination of geniposide in adjuvant arthritis rat plasma by ultra-high performance liquid chromatography tandem mass spectrometry method and its application to oral bioavailability and plasma protein binding ability studies.
Chen J; Wu H; Xu GB; Dai MM; Hu SL; Sun LL; Wang W; Wang R; Li SP; Li GQ
J Pharm Biomed Anal; 2015 Apr; 108():122-8. PubMed ID: 25771205
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of LC-MS/MS methods for the quantification of 101BHG-D01, a novel, long-acting and selective muscarinic receptor antagonist, and its main metabolite M6 in human plasma, urine and feces: Application to a clinical study in healthy Chinese subjects.
Gao H; Cheng M; Liu H; Ding L
J Pharm Biomed Anal; 2023 Sep; 233():115498. PubMed ID: 37285657
[TBL] [Abstract][Full Text] [Related]
20. Development and Validation of a Simultaneous Quantification Method of Ruxolitinib, Vismodegib, Olaparib, and Pazopanib in Human Plasma Using Liquid Chromatography Coupled With Tandem Mass Spectrometry.
Pressiat C; Huynh HH; Plé A; Sauvageon H; Madelaine I; Chougnet C; Le Maignan C; Mourah S; Goldwirt L
Ther Drug Monit; 2018 Jun; 40(3):337-343. PubMed ID: 29474275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
